ELTX vs ENGN

Elicio Therapeutics, Inc. vs enGene Therapeutics Inc. — Valuation Comparison 2026

ELTX

Biotechnology
Elicio Therapeutics, Inc.
Quality
4.1
out of 10
Value Trap
30
LOW
Price
$10.61
Last close
Models
7/13
Active
VS

ENGN

Biotechnology
enGene Therapeutics Inc.
Quality
4.1
out of 10
Value Trap
12
SAFE
Price
$1.78
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType ELTX Fair ValueELTX Upside ENGN Fair ValueENGN Upside
Bayesian DCF Intrinsic $2.98 -71.9% $0.58 -67.6%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $5.01 -52.7% $1.92 +8.1%
Dynamic NAV Asset-Based $0.32 -97.0% $3.11 +74.7%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ELTX vs ENGN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ELTX vs ENGN — Which Stock Is More Undervalued?

ENGN scores higher with a 4.1/10 quality rating vs ELTX's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Elicio Therapeutics, Inc. (ELTX) and enGene Therapeutics Inc. (ENGN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ELTX currently trades at $10.61 with a QOC of 4.1/10, while ENGN trades at $1.78 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).